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The  safety  proﬁle  of  afoxolaner,  a new  isoxazoline  molecule,  was  evaluated  following  the
regulatory  requirements  when  administered  six times  orally  in  a soft  chewable  formulation
at a dose  of  at  least  1×, 3×  or 5×  the  maximum  exposure  dose  (6.3  mg/kg)  in 8-week-old
Beagle  dogs.  Thirty-two  healthy  puppies  (16 males  and  16 females)  were enrolled  and allo-
cated randomly  to one  of four treatment  groups.  Treatments  were  administered  at  three,
one-month  dose  intervals  (Days  0,  28  and 56)  followed  by  three,  2-week  dose  intervals  (Days
84,  98  and  112).  The  study  ended  at Day  126.  The  groups  were:  Group  1: non-treated  con-
trol; Group  2:  afoxolaner  chews  administered  at a  dosage  of  at  least 6.3  mg/kg  (1×);  Group
3: afoxolaner  chews  administered  at a dosage  of  at least  18.9  mg/kg  (3×);  and  Group  4:
afoxolaner  chews  administered  at a dosage  of  at least  31.5  mg/kg  (5×). All dogs  were  exam-
ined for general  health  twice  a day  beginning  on at least  Day-14.  Physical  examinations,
and  blood  collections  for clinical  pathology  analysis  and  afoxolaner  plasma  concentrations,
were  performed  throughout  the  study.  On  Day  126, 2  weeks  following  the  last treatment,
all  dogs  were  humanely  euthanized  prior  to  the  conduction  of  a full  necropsy  with  tissue
collection.
No afoxolaner-related  changes  were  observed  in  growth,  physical  variables,  clinical
pathology  variables,  or tissues  examined  histologically.  No  clinically  or statistically  sig-
niﬁcant health  abnormalities  related  to the  administration  of afoxolaner  were  observed.
Vomiting  and  diarrhea  were  observed  sporadically  across  all groups  including  the  controls.
The kinetics  of  afoxolaner  plasma  concentrations  was  linear  following  6 doses  of 6.3, 18.9
and 31.5  mg/kg  and  dose  proportionality  was demonstrated.  There  were  no  statistical  dif-
ferences (p  <  0.05)  between  samples  taken  on Days  55  and  83 when  compared  to  Day  27.
Based upon  the results  of  this  study,  afoxolaner  was  shown  to  be  safe  when  administered
repeatedly  in  a soft chewable  formulation  at up  to 5× the maximum  exposure  dose  in dogs
as young  as 8  weeks  of age.
© 2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
Y-NC-NB
1. IntroductionAdvances in research for ectoparasitological control
have brought new therapeutic drugs forward for clinical
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usage (e.g., ﬁpronil, imidacloprid and spinosad) (Beugnet
and Franc, 2012). Afoxolaner is a compound from a new
structurally unique isoxazoline class which acts as a novel
and speciﬁc blocker of insect ligand-gated chloride ion
channels (Shoop et al., 2014). It was formulated in a unique
soft, beef-ﬂavored chew (Nexgard®, Merial). There are four
chew sizes, of respectively 0.5 g, 1.25 g, 3 g and 6 g, con-
taining 11.3 mg,  28.3 mg,  68 mg  and 136 mg  of afoxolaner.
ss article under the CC BY-NC-ND license (http://creativecommons.org/
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Table  1
Description of afoxolaner treatment groups.
Treatment group (number of dogs) Treatment (dose; route) Treatment days
1 (8a) Control (not applicable)
0, 28, 56, 84, 98, 112
2  (8a) 1× afoxolaner (≥6.3 mg/kg; oral)
a
 (≥18.9
 (≥31.5
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m3  (8 ) 3× afoxolaner
4  (8a) 5× afoxolaner
a Equal numbers of each sex were included.
hey are intended for dogs weighing 2–4 kg, 4.1–10 kg,
0.1–25 kg and 25.1–50 kg, respectively. The weight bands
f the various chew sizes can result in a minimum thera-
eutic dose of 2.5 mg/kg and a maximum exposure dose of
.3 mg/kg body weight.
The assessment of the safety of a compound in the tar-
et species is a prerequisite for registration of veterinary
roducts. The guidelines for target animal safety studies
ow require that the compound be tested using the ﬁnal
ommercial formulation at 1, 3, and 5 times the maxi-
um  exposure dose (VICH, 2008). Oral as well as topically
pplied antiparasitic drugs are usually manufactured so
hat one size tablet/chewable or pipette can be adminis-
ered to animals within a speciﬁed weight range (Blagburn
t al., 2010). The dose received by the heaviest animal in
he range is designated as the minimum therapeutic dose.
he dose received by the lightest animal in the range is
esignated the maximum exposure dose. The maximum
xposure dose must then be multiplied by 1, 3, and 5
imes. The regulatory guidelines also determine the num-
er of times a formulation must be administered during
he study and in addition to the minimum age of animals
o be tested. The formulation is recommended to be admin-
stered monthly for six treatments. If a product is designed
or use in young animals, the age of the animal tested must
e the minimum age for which the commercial product
ill be used. Establishment of safety for use in the target
pecies and for animal at a minimum age is mandatory to
et a registration as veterinary medicine. It is necessary to
emonstrate to the veterinarians and the pet owners that
o unexpected adverse event will occur in treated dogs.
Therefore, the objective of this study was to determine
he safety proﬁle of afoxolaner administered in a soft chew-
ble formulation to 8-week-old dogs at either 1×, 3× or 5×
he maximum exposure dose (i.e., 6.3 mg/kg, 18.9 mg/kg
nd 31.5 mg/kg) at three, one-month-dose-intervals fol-
owed by three, 2-week-dose intervals.
. Materials and methods
This study design followed the recommendations of
ICH Guideline GL 43 “Target Animal Safety – Pharmaceut-
cals: Target Animal Safety for Veterinary Pharmaceutical
roducts” (VICH, 2008), and was conducted in accordance
ith the Food and Drug Administration; Good Laboratory
ractice Regulations for Non-Clinical Laboratory Studies,
1 CFR Part 58, which is also accepted under the Orga-
ization for Economic Co-operation Development (OECD)
rinciples of Good Laboratory Practice (Revised 1997,
ssued January 1998) ENV/MC/CHEM(98)17, OECD Com-
ission Directive 1999/11/EC of 08 March 1999. All animal mg/kg; oral)
 mg/kg; oral)
procedures in this study were reviewed and approved by
the Merial Institutional Animal Care and Use Committee
(IACUC). Dogs were managed consistent with the US Ani-
mal  Welfare Regulations (USDA, 2008).
3. Animals
Thirty-two beagle dogs (16 males and 16 females) were
included in the study. The dogs were 8.1–9.3 weeks of age
on Day 0 and weighed 2.25–4.00 kg on Day −2. Dogs had
not been exposed to ectoparasiticides prior to treatment
and were in good health.
They were fed a commercial dry dog food ration calcu-
lated to maintain a healthy physical state and water was
available ad libitum. Housing was in an environmentally
controlled building. After allocation and until Day 20, two
dogs of the same treatment group were co-housed. On Day
0 post dosing and from Day 21 to study end, dogs were
housed individually and provided socialization time daily.
4. Experimental design
A random block design was chosen for allocation. Dogs
were weighed on Day −2 and were ranked by decreasing
body weight within sex and blocks of four dogs each were
formed. Within each block, dogs were allocated randomly
to one of the four treatment groups (Table 1) using the pro-
cedure Plan in SAS® Version 9.1.3. The ﬁnal soft chewable
formulation of afoxolaner for oral administration was man-
ufactured under current Good Manufacturing Practices at
Merial Limited. Three sizes were used: 0.5 g (11.3 mg afox-
olaner); 1.25 g (28.3 mg  afoxolaner); and 3 g soft chewables
(68.0 mg  afoxolaner).
Dose rate calculations were based on the body weight
obtained at the most recent physical examination. As the
chews cannot be divided, the number of chews admin-
istered, made up of identical or various sizes, was the
number closest to, but not less than, the total mg dose
needed (e.g., 1.95 kg bodyweight × 18.9 mg/kg = 36.86 mg
afoxolaner; one 0.5 g and one 1.25 g chew = 39.7 mg  afox-
olaner for a treatment group 3 dog (Table 1).
Treatments were administered at one-month dose
intervals at Days 0, 28 and 56, and then at 2-week dose
intervals (at Days 84, 98 and 112). On each designated
treatment day, control dogs were handled similarly to the
treated dogs but were not dosed. Dogs in 1× group were
treated with the required dose of afoxolaner chews pro-
vided in a single fraction. Due to the volume of chewable
material to be provided, dogs in 3× and 5× groups received
approximately half of their required dose (ﬁrst fraction) ini-
tially, with the rest of the required dose (second fraction)
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administered approximately 3 h later. The dose was  divided
into two fractions for puppies in the 3× and 5× groups so
that over-distension of the stomach would not occur. To
avoid bias, control and dogs in the 1× groups were han-
dled similarly to the other two groups but were not dosed
during the administration of the second fraction. Food was
offered to the dogs prior to and after each treatment.
Dogs were observed at least hourly for 3 h after the ﬁrst
dose fraction was administered and hourly for 4 h after
the second dose fraction was administered. Feces from all
dogs were examined for the presence of whole undigested
chews on the day after treatment.
Personnel involved with recording of the in-life obser-
vations were blinded as to treatment. The pathologist
performing the necropsy was unaware of dog’s group but
the origin of the dogs was unblinded for the histologic eval-
uation.
5. Study outcome evaluation
Physical examinations were performed weekly during
the pre-test period and biweekly to Day 125, and included
the evaluation of the general appearance, body weight,
respiration rate, heart rate, and body temperature. Daily
feed intake was monitored and recorded for analysis begin-
ning on Day −1. In addition, blood hematology, plasma
chemistry, and coagulation proﬁles were determined twice
during pre-test in conjunction with physical examinations
on Days 14, 27, 42, 55, 70, 83, 97, 111 and 125. Standard lab-
oratory techniques were used for collection and analysis of
the samples. The Merial laboratory conducting the analysis
provided reference ranges for the plasma chemistry, coag-
ulation, and hematology proﬁles. The hematology proﬁle
included: red blood cell count (RBC), white blood cell count,
white blood cell differentials (absolute count), platelet
count, hemoglobin, hematocrit, mean corpuscular volume,
mean corpuscular hemoglobin, mean cell hemoglobin con-
centration, and RBC morphology. The plasma chemistry
proﬁle included: alanine aminotransferase, albumin, alka-
line phosphatase, amylase, aspartate aminotransferase,
calcium, chloride, cholesterol, creatinine, globulin, glu-
cose, phosphorus, potassium, sodium, total bilirubin, total
protein, triglycerides, and urea nitrogen. The coagulation
proﬁle included activated partial thromboplastin time, pro-
thrombin time, and thrombin clotting time. Urine samples
were obtained once during pretest and on Days 27 and
126 using either a metabolism pan or by cystocentesis
(Day 126). Urinalysis included determination of urobilino-
gen, nitrite, glucose, bilirubin, ketones, blood, leukocytes,
speciﬁc gravity, pH, and protein by use of MULTISTIX®
SG Reagent Strips (Bayer Corporation). In addition to the
reagent strips, a refractometer was used to determine urine
speciﬁc gravity. Urine sediment was evaluated microscop-
ically for at least the following: crystals, casts, red blood
cells, white blood cells, and epithelial cells. Standard lab-
oratory techniques were used. Reference ranges for the
speciﬁc gravity was from Stockham and Scott (2002).
Dogs were humanely euthanized on Day 126 and a
complete post-mortem examination was conducted. Sam-
ples of the pertinent tissues and representative sampleslogy 201 (2014) 198–203
of tissues containing gross lesions were collected and
processed for histological examination.
Blood samples for analysis of afoxolaner concentration
were collected as either part of the samples collected for
clinical chemistry analysis or were collected separately
3 h after treatment on Day 112. Plasma samples were
analyzed quantitatively to determine afoxolaner concen-
trations using a method based on 96-well solid phase
extraction of afoxolaner from canine plasma and a pro-
prietary internal standard followed by LC–MS analysis as
described in Letendre et al. (2014).
6. Data analysis
The physical exam, continuous clinical pathology val-
ues, and urinalysis were analyzed over the full study. The
analysis of these variables used repeated measures analysis
of covariance (RMANCOVA), including treatment, sampling
day, sex, and their interaction terms as ﬁxed effects. The
covariate was  the most recent pre-treatment value. If the
three-way interaction, “treatment by sex by sampling day”,
was  signiﬁcant at the p = 0.05 level, then no further evalu-
ation was done. If the “treatment by sex by sampling day”
interaction was not signiﬁcant, then “treatment by sex” and
“treatment by sampling day” were evaluated. If either two-
way  interaction was signiﬁcant, then the treatment means
were compared to the control group within each level of the
corresponding factor. If neither was  signiﬁcant, the effect
of treatment was evaluated and if signiﬁcant, the treatment
means were compared to the control group. Other than the
test of the three-way interaction, all statistical analyses
used p = 0.10 signiﬁcance level. When compared to efﬁ-
cacy testing of molecules where a signiﬁcance level <0.05
is needed, the choice of 0.10 signiﬁcance level for animal
safety study increases the safety margin by highlighting
effects that would not appear at p < 0.05.
During the study, commercial food was offered at least
twice daily and total daily consumption was  analyzed.
Organ weights (absolute, per 100 g body weight and per
100 g brain weight) were analyzed using analysis of vari-
ance (ANOVA).
Abnormal health ﬁndings were summarized by treat-
ment group using Veterinary Medicinal Dictionary for Drug
Regulatory Authorities (VEDDRA) terms (EMA, 2013). For
the analysis of health abnormalities, the analysis endpoint
was  the number of dogs within each treatment group
that experienced that abnormality at least once during the
study. If a treatment group other than control had at least
4 animals experiencing the abnormality, then the three
treated groups were compared to the control group using
the Pearson Chi-Square test on a pair-wise basis. The only
abnormalities analyzed in this manner were emesis and
diarrhea.
Nine plasma samples over 126 days from each treated
dog were collected in order to establish afoxolaner plasma
concentrations during the study. Samples were taken prior
to each treatment to establish that steady state had been
reached during monthly dosing. Samples were also taken
3 h after dosing which is in the range of the maximum
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reatment (Letendre et al., 2014).
. Results
No clinically relevant afoxolaner-related changes were
bserved in feed consumption, body weight, or physical
xamination parameters (i.e., heart rate, respiratory rate,
nd body temperature) at any of the sampling periods
cheduled throughout the 126 days of the study cover-
ng the 6 treatment administrations. The only statistically
igniﬁcant difference was in the overall mean respiratory
ate that was slightly higher than the overall mean con-
rol value in female dogs administered either 1× or 3×,
nd in male dogs administered 5× the maximum dose of
foxolaner. These changes in mean respiratory rate were
light, not changed in a time or dose-related manner,
nd within the expected respiratory range for matur-
ng, active growing puppies. No clinically or statistically
igniﬁcant health abnormalities related to the adminis-
ration of afoxolaner were observed, however, vomiting
nd diarrhea were observed sporadically across all groups,
ncluding the controls. One dog in the 5× group vom-
ted 4 h after treatment. The monthly/biweekly exposure
o afoxolaner did not cause incremental increase in the
ncidences of vomiting and diarrhea in any of the treatedeated control, Group 2 = 1× afoxolaner (≥6.3 mg/kg; oral), Group 3 = 3×
groups. Occasional vomiting and diarrhea did not inter-
fere with daily food consumption or normal growth in
the puppies (Fig. 1). No afoxolaner-related changes were
observed at necropsy or in H&E stained microscopic tissue
sections. There were no changes in organ weights. Accord-
ingly, there were no clinically relevant afoxolaner-related
changes in hematology, plasma chemistry, coagulation
proﬁles, or urinalysis parameters at any of the sampling
periods scheduled throughout the in-life period. Statis-
tically signiﬁcant (p < 0.05) changes in mean corpuscular
hemoglobin concentration, red blood cell counts, basophils,
albumin, calcium, phosphorus, and sodium were observed
in different groups during the study. The ﬂuctuations in
clinical pathology variables were slight and did not change
in a time- or dose-responsive manner. All group means fell
within the laboratory’s historical control ranges for matur-
ing Beagle dogs.
Afoxolaner steady state plasma concentrations were
reached by Day 27 as demonstrated by the lack of statis-
tically signiﬁcant differences (p > 0.05) between pre-dose
samples taken on Days 27, 55 and 83 (Table 3). Dose pro-
portionality was  demonstrated and mean Cmin values on
Days 27, 55 and 83 ranged from 138.8 to 197.6 ng/mL, 273.2
to 472.5 ng/mL, and 629.5 to 954.1 ng/mL following the
6.3 mg/kg, 18.9 mg/kg and 31.5 mg/kg treatments, respec-
tively (Table 2). Concentrations increased as expected
202 M.  Drag et al. / Veterinary Parasito
Table 2
Afoxolaner plasma concentrations (ng/mL) taken one day prior to next
treatment.
Treatment group (dose) Pre-dose afoxolaner concentrations
(ng/mL)
Day 27 Day 55 Day 83
1× (≥6.3 mg/kg) 167.0 138.8 197.6
p Valueb 0.50 0.002a 0.33
3× (≥18.9 mg/kg) 273.2 387.5 472.5
p Valueb 0.22 0.86 0.32
5× (≥31.5 mg/kg) 629.5 674.4 954.1
p Valueb 0.818 0.019a 0.121
a Bold indicates a p value < 0.05 indicating a statistical difference
between Day 55 and Day 83 afoxolaner plasma concentrations was noted
for  the lowest and highest dose group; however, no trend was observed
either with dose or with the three time points examined. This difference
therefore does not indicate that steady state has not been reached.
b p-Values are from a 2-tailed paired Student’s T-test for concentrations
on  Day 27 and 55 (D27–55), Days 55 and 83 (D55–83) and Days 27 and 83
(D27–83).
Table 3
Mean ± SD of Cmax of afoxolaner plasma concentrations (ng/mL) on Day
112  (∼3 h post treatment).
Treatment group (dose) Cmax (ng/mL)Group 2 – 1× (≥6.3 mg/kg) 4010 ± 660
Group 3 – 3× (≥18.9 mg/kg) 9370 ± 3360
Group 4 – 5× (≥31.5 mg/kg) 16 400 ± 4400
following the transition to 2-week dosing intervals. Max-
imum measured plasma concentrations (Cmax values)
following the ﬁnal treatment on Day 112 (∼3 h post treat-
ment) were 4010 ± 660 ng/mL, 9370 ± 3360 ng/mL, and
16 400 ± 4400 ng/mL for the 6.3 mg/kg, 18.9 mg/kg and
31.5 mg/kg dose levels, respectively (Table 4).
8. Discussion
Afoxolaner was well tolerated when administered at
1×, 3× or 5× the maximum exposure dose to Beagle dogs
as young as 8 weeks of age for six treatments. No clin-
ically relevant treatment-related changes were observed
for physical examination variables, clinical pathology, gross
pathology, histopathology, or organ weights.
To get their approval, new animal health products are
required to be tested for safety at 1, 3, and 5 times the max-
imum exposure dose using the formulation designated for
commercial use. The minimum therapeutic dose of afox-
olaner is 2.5 mg/kg (Letendre et al., 2014). The calculation
of the maximum exposure dose is dependent on the weight
ranges developed for the commercial presentations. For
Table 4
Ranges of afoxolaner doses administered to the dogs.
Dog group Dose range
(mg/kg)
Avera
thera
Group 2 (1×)  6.36–8.22 2.8 
Group  3 (3×) 18.98–22.42 8.0 
Group  4 (5×)  31.57–35.49 13 
a Therapeutic dose = 2.5 mg/kg.
b Maximum exposure dose = 6.3 mg/kg.logy 201 (2014) 198–203
products that are dosed on a speciﬁed mg/kg dosage (i.e.,
injectables), the therapeutic dose and the maximum expo-
sure can be similar. For afoxolaner, the maximum exposure
dose (6.3 mg/kg) is the highest dose that the lightest ani-
mal  in a particular weight range will receive when dosed
according to the label directions (Table 4).
Not only must the maximum exposure dose be admin-
istered but the number of treatments received by each
animal is also deﬁned by the product indications. For veteri-
nary products intended to be used monthly, the regulatory
agencies could require that the product be administered for
six treatments, monthly or every 2 weeks for three months.
In this study, afoxolaner was administered 6 times; the
ﬁrst three doses at a monthly interval and the last three
doses at a 14 day interval. This schedule was proposed in
relation to the pharmacokinetic data of afoxolaner, in order
to be sure that short intervals would not lead to accumula-
tion of afoxolaner (Shoop et al., 2014; Letendre et al., 2014).
Plasma afoxolaner concentrations reached steady state fol-
lowing the second monthly dose. This result was expected
because the terminal plasma half-life is on average 18 days.
At all dose levels tested, the kinetic proﬁle of afoxolaner in
the target animal safety study was  predictable and con-
sistent with the extensive preclinical evaluation (Letendre
et al., 2014).
The higher plasma values were not associated with any
adverse ﬁndings in the dogs thus adding to the margin of
safety.
Regulatory requirements also guide which age of ani-
mals are to be tested. If a product is to be used in young
animals, the study should include animals of the minimum
age. Testing afoxolaner in young dogs at the maximum
exposure dose for 6 treatments in an accelerated man-
ner should highlight any potential safety concerns. The
youngest dogs when this study began were 8.1 weeks. The
maximum exposure dose and the accelerated treatment
administration were all well tolerated in these puppies
when ﬁrst treated and continued as they matured.
Vomiting and diarrhea did occur sporadically during
the study, however, the incidence was  similar across all
groups, including the untreated controls. Occasional vomi-
ting and diarrhea are expected background observations
in young dogs. The vomiting observed was usually of
a small amount, limited to a single episode during a
day, not associated with the time of food consumption,
and resolved without any medical or dietary interven-
tion. Observations of feces were performed at least twice
daily and each observation spanned the time since the
last observation. The change in consistency of the feces
was  normally observed in only one of several bowel
movements that were present in the cage. In the majority of
ge multiple of
peutic dosea
Average multiple of maximum
exposure doseb
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ases, the other bowel movements that were present were
ormal. As with vomiting, the diarrhea observed across all
roups and was usually of a small amount, limited to a sin-
le episode during a day, and resolved without any medical
r dietary intervention. Occasional vomiting and diarrhea
id not interfere with daily food consumption or normal
rowth in the puppies (Fig. 1). No particular pattern was
dentiﬁed to link vomiting or diarrhea to a disease as all
ogs appear clinically healthy during the study and all clin-
cal pathology results and histopathology of the digestive
ract appeared normal.
The metabolic systems of juvenile dogs at 8 weeks of
ge are still developing thus administration of veterinary
edicine to this age animal may  have more profound
ffects than when administered to adults. Changes in body
eight and daily feed consumption are excellent indicators
hat effects are occurring. Food in the study was offered
wice daily and monitored, thus a decrease in food con-
umption would have been readily apparent. Body weight
s a reﬂection of the food consumption and normal growth.
he body weight curves of all the dogs in this study were
onsistent throughout all four groups (Fig. 1). The ﬁnal body
eights in all groups in this study are reﬂective of the excel-
ent health of the dogs at the conclusion of the study.
. Conclusion
The results of this study demonstrate that afoxolaner is
afe when administered to dogs between 8 and 24 weeks
f age, six separate times in a soft chewable formulation at
p to 5× the maximum exposure dose.onﬂict of interest
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